Ritobegron

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ritobegron
Accession Number
DB12080
Type
Small Molecule
Groups
Investigational
Description

Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers).

Structure
Thumb
Synonyms
Not Available
External IDs
KUC-7483
Categories
UNII
LD86RKR53M
CAS number
255734-04-4
Weight
Average: 373.449
Monoisotopic: 373.188922973
Chemical Formula
C21H27NO5
InChI Key
VMMYRRFPMAGXNP-BTYIYWSLSA-N
InChI
InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
IUPAC Name
2-[4-(2-{[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)-2,5-dimethylphenoxy]acetic acid
SMILES
C[C@H](NCCC1=C(C)C=C(OCC(O)=O)C(C)=C1)[C@H](O)C1=CC=C(O)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Ritobegron.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Ritobegron.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Ritobegron.Approved
AcrivastineRitobegron may decrease the sedative activities of Acrivastine.Approved
AlcaftadineRitobegron may decrease the sedative activities of Alcaftadine.Approved
AlfentanilRitobegron may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
AlimemazineRitobegron may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
AlphacetylmethadolRitobegron may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineRitobegron may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
AmineptineAmineptine may increase the stimulatory activities of Ritobegron.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Ritobegron.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Ritobegron.Approved
AmitriptylinoxideAmitriptylinoxide may increase the stimulatory activities of Ritobegron.Approved, Investigational
Ammonium chlorideThe serum concentration of Ritobegron can be decreased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmoxapineAmoxapine may increase the stimulatory activities of Ritobegron.Approved
AmperozideAmperozide may decrease the stimulatory activities of Ritobegron.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Amphetamine.Approved, Illicit, Investigational
AntazolineRitobegron may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Ritobegron.Approved, Investigational
Ascorbic acidThe serum concentration of Ritobegron can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
AsenapineAsenapine may decrease the stimulatory activities of Ritobegron.Approved
AstemizoleRitobegron may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of Ritobegron.Investigational, Vet Approved
AzatadineRitobegron may decrease the sedative activities of Azatadine.Approved
AzelastineRitobegron may decrease the sedative activities of Azelastine.Approved
BamipineRitobegron may decrease the sedative activities of Bamipine.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when Ritobegron is combined with Benmoxin.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Ritobegron.Approved, Investigational
BenzatropineRitobegron may decrease the sedative activities of Benzatropine.Approved
BenzquinamideRitobegron may decrease the sedative activities of Benzquinamide.Withdrawn
Benzylpenicilloyl PolylysineRitobegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepotastineRitobegron may decrease the sedative activities of Bepotastine.Approved
BetahistineRitobegron may decrease the sedative activities of Betahistine.Approved, Investigational
BevantololBevantolol may decrease the vasoconstricting activities of Ritobegron.Approved
BezitramideRitobegron may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Ritobegron.Investigational
BilastineRitobegron may decrease the sedative activities of Bilastine.Approved, Investigational
Bismuth subcitrate potassiumBismuth Subcitrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Ritobegron.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved, Investigational
BromodiphenhydramineRitobegron may decrease the sedative activities of Bromodiphenhydramine.Approved
BromperidolBromperidol may decrease the stimulatory activities of Ritobegron.Approved, Investigational
BrompheniramineRitobegron may decrease the sedative activities of Brompheniramine.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Ritobegron.Investigational
BuclizineRitobegron may decrease the sedative activities of Buclizine.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
BuprenorphineRitobegron may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Ritobegron.Experimental
ButorphanolRitobegron may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
ButriptylineButriptyline may increase the stimulatory activities of Ritobegron.Approved
Butyric AcidRitobegron may decrease the sedative activities of Butyric Acid.Experimental, Investigational
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
CarbinoxamineRitobegron may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilRitobegron may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Ritobegron is combined with Caroxazone.Withdrawn
CarvedilolCarvedilol may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
CetirizineRitobegron may decrease the sedative activities of Cetirizine.Approved
ChlorcyclizineRitobegron may decrease the sedative activities of Chlorcyclizine.Approved
ChloropyramineRitobegron may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineRitobegron may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineRitobegron may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Ritobegron.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Ritobegron.Approved, Investigational, Withdrawn
CimetidineRitobegron may decrease the sedative activities of Cimetidine.Approved, Investigational
CinnarizineRitobegron may decrease the sedative activities of Cinnarizine.Approved, Investigational
ClemastineRitobegron may decrease the sedative activities of Clemastine.Approved, Investigational
ClofedanolRitobegron may decrease the sedative activities of Clofedanol.Approved, Withdrawn
ClomipramineClomipramine may increase the stimulatory activities of Ritobegron.Approved, Investigational, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Ritobegron.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Ritobegron.Experimental
ClozapineClozapine may decrease the stimulatory activities of Ritobegron.Approved
CodeineRitobegron may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Ritobegron.Approved
CyclizineRitobegron may decrease the sedative activities of Cyclizine.Approved
CyproheptadineRitobegron may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Ritobegron.Approved
DesipramineDesipramine may increase the stimulatory activities of Ritobegron.Approved, Investigational
DesloratadineRitobegron may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Ritobegron.Approved, Investigational
DexbrompheniramineRitobegron may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineRitobegron may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateRitobegron may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Ritobegron.Approved, Illicit
DextromoramideRitobegron may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneRitobegron may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineRitobegron may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of Ritobegron.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
DihydrocodeineRitobegron may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved, Investigational
DihydroetorphineRitobegron may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineRitobegron may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateRitobegron may decrease the sedative activities of Dimenhydrinate.Approved
DimetacrineDimetacrine may increase the stimulatory activities of Ritobegron.Approved, Withdrawn
DimetindeneRitobegron may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazineRitobegron may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineRitobegron may decrease the sedative activities of Diphenhydramine.Approved, Investigational
DiphenoxylateRitobegron may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DiphenylpyralineRitobegron may decrease the sedative activities of Diphenylpyraline.Approved, Investigational
DixyrazineDixyrazine may decrease the stimulatory activities of Ritobegron.Experimental
DosulepinDosulepin may increase the stimulatory activities of Ritobegron.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Ritobegron.Approved
DoxepinRitobegron may decrease the sedative activities of Doxepin.Approved, Investigational
DoxylamineRitobegron may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPERitobegron may increase the analgesic activities of DPDPE.Experimental
DronedaroneDronedarone may decrease the vasoconstricting activities of Ritobegron.Approved
DroperidolDroperidol may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Ritobegron.Approved
EbastineRitobegron may decrease the sedative activities of Ebastine.Approved, Investigational
EcopipamEcopipam may decrease the stimulatory activities of Ritobegron.Investigational
EmedastineRitobegron may decrease the sedative activities of Emedastine.Approved
EpinastineRitobegron may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineEpinephrine may decrease the vasoconstricting activities of Ritobegron.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved
EscitalopramEscitalopram may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
EsmirtazapineRitobegron may decrease the sedative activities of Esmirtazapine.Investigational
EthopropazineRitobegron may decrease the sedative activities of Ethopropazine.Approved
EthosuximideRitobegron can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Withdrawn
EthylmorphineRitobegron may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtoperidoneRitobegron may decrease the sedative activities of Etoperidone.Withdrawn
EtorphineRitobegron may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineRitobegron may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Ritobegron.Approved, Illicit, Withdrawn
FentanylRitobegron may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineRitobegron may decrease the sedative activities of Fexofenadine.Approved, Investigational
FluanisoneFluanisone may decrease the stimulatory activities of Ritobegron.Experimental
FlunarizineRitobegron may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Ritobegron.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Ritobegron.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Ritobegron.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Ritobegron.Approved, Investigational, Vet Approved
Glutamic AcidThe serum concentration of Ritobegron can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Ritobegron can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Ritobegron.Approved
HarmalineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Harmaline.Experimental
HeroinRitobegron may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Hydracarbazine.Experimental
HydrocodoneRitobegron may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneRitobegron may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Experimental, Investigational
HydroxyzineRitobegron may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Ritobegron.Approved
ImipramineImipramine may increase the stimulatory activities of Ritobegron.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Ritobegron.Withdrawn
Ioflupane I-123Ritobegron may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Ritobegron.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Ritobegron is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Ritobegron.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Ritobegron.Approved
IsothipendylRitobegron may decrease the sedative activities of Isothipendyl.Approved
KetobemidoneRitobegron may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenRitobegron may decrease the sedative activities of Ketotifen.Approved
LabetalolLabetalol may decrease the vasoconstricting activities of Ritobegron.Approved
LafutidineRitobegron may decrease the sedative activities of Lafutidine.Investigational
LavoltidineRitobegron may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineRitobegron may decrease the sedative activities of Levocabastine.Approved, Investigational
LevocetirizineRitobegron may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateRitobegron may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Ritobegron.Approved, Investigational
LevorphanolRitobegron may increase the analgesic activities of Levorphanol.Approved
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
Lithium cationLithium may decrease the stimulatory activities of Ritobegron.Experimental
LodoxamideRitobegron may decrease the sedative activities of Lodoxamide.Approved
LofentanilRitobegron may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Ritobegron.Experimental
LoratadineRitobegron may decrease the sedative activities of Loratadine.Approved, Investigational
LorpiprazoleRitobegron may decrease the sedative activities of Lorpiprazole.Approved
LoxapineLoxapine may decrease the stimulatory activities of Ritobegron.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Ritobegron.Approved, Investigational
MagaldrateMagaldrate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved, Investigational
Magnesium oxideMagnesium oxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
MaprotilineRitobegron may decrease the sedative activities of Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Mebanazine.Withdrawn
MeclizineRitobegron may decrease the sedative activities of Meclizine.Approved
MelitracenMelitracen may increase the stimulatory activities of Ritobegron.Experimental, Investigational
MelperoneMelperone may decrease the stimulatory activities of Ritobegron.Approved, Investigational
MeptazinolRitobegron may increase the analgesic activities of Meptazinol.Experimental
MepyramineRitobegron may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineRitobegron may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
MethadoneRitobegron may increase the analgesic activities of Methadone.Approved
Methadyl AcetateRitobegron may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethanthelineRitobegron may decrease the sedative activities of Methantheline.Approved, Investigational
MethapyrileneRitobegron may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
MethdilazineRitobegron may decrease the sedative activities of Methdilazine.Approved
MethenamineThe serum concentration of Ritobegron can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
Methylene blueThe risk or severity of adverse effects can be increased when Ritobegron is combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Ritobegron.Approved
MetiamideRitobegron may decrease the sedative activities of Metiamide.Experimental
MianserinRitobegron may decrease the sedative activities of Mianserin.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Ritobegron.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Ritobegron.Approved
MirtazapineRitobegron may decrease the sedative activities of Mirtazapine.Approved
MizolastineRitobegron may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Ritobegron.Approved, Investigational
MolindoneMolindone may decrease the stimulatory activities of Ritobegron.Approved
MoperoneMoperone may decrease the stimulatory activities of Ritobegron.Experimental
MorphineRitobegron may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Ritobegron.Experimental
NalbuphineRitobegron may increase the analgesic activities of Nalbuphine.Approved
NefazodoneNefazodone may decrease the vasoconstricting activities of Ritobegron.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Ritobegron.Withdrawn
NicardipineNicardipine may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
NicomorphineRitobegron may increase the analgesic activities of Nicomorphine.Experimental
NiguldipineNiguldipine may decrease the vasoconstricting activities of Ritobegron.Experimental
NizatidineRitobegron may decrease the sedative activities of Nizatidine.Approved
NormethadoneRitobegron may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Ritobegron.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Ritobegron is combined with Octamoxin.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
OlopatadineRitobegron may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Ritobegron.Approved
OpipramolOpipramol may increase the stimulatory activities of Ritobegron.Investigational
OpiumRitobegron may increase the analgesic activities of Opium.Approved, Illicit
OrphenadrineRitobegron may decrease the sedative activities of Orphenadrine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Ritobegron.Investigational
OxatomideRitobegron may decrease the sedative activities of Oxatomide.Investigational
OxycodoneRitobegron may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneRitobegron may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Ritobegron.Experimental
OzagrelRitobegron may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Ritobegron.Approved
PargylinePargyline may increase the hypertensive activities of Ritobegron.Approved
PemirolastRitobegron may decrease the sedative activities of Pemirolast.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Ritobegron.Experimental
PentazocineRitobegron may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
PerospironePerospirone may decrease the stimulatory activities of Ritobegron.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Ritobegron.Approved
PethidineRitobegron may increase the analgesic activities of Pethidine.Approved
PhenazocineRitobegron may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Ritobegron.Approved
PhenindamineRitobegron may decrease the sedative activities of Phenindamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Pheniprazine.Withdrawn
PheniramineRitobegron may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Ritobegron.Approved, Investigational
PhenoperidineRitobegron may increase the analgesic activities of Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may decrease the vasoconstricting activities of Ritobegron.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Phenoxypropazine.Withdrawn
PhentolaminePhentolamine may decrease the vasoconstricting activities of Ritobegron.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Ritobegron.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Ritobegron.Approved
PipamperonePipamperone may decrease the stimulatory activities of Ritobegron.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
PiritramideRitobegron may increase the analgesic activities of Piritramide.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Ritobegron.Approved
PitolisantRitobegron may decrease the sedative activities of Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Pivhydrazine.Withdrawn
PizotifenPizotifen may decrease the vasoconstricting activities of Ritobegron.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Ritobegron.Approved
ProcaineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Procarbazine.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
PromethazineRitobegron may decrease the sedative activities of Promethazine.Approved, Investigational
PropericiazinePropericiazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Ritobegron.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
ProthipendylProthipendyl may decrease the stimulatory activities of Ritobegron.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Ritobegron.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Ritobegron.Approved
QuifenadineRitobegron may decrease the sedative activities of Quifenadine.Experimental
QuinidineQuinidine may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Ritobegron.Approved
RacloprideRaclopride may decrease the stimulatory activities of Ritobegron.Investigational
RanitidineRitobegron may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Ritobegron.Approved
RemifentanilRitobegron may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Ritobegron.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
RisperidoneRisperidone may decrease the stimulatory activities of Ritobegron.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Ritobegron.Investigational
Roxatidine acetateRitobegron may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
RupatadineRitobegron may decrease the sedative activities of Rupatadine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Safrazine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Ritobegron is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Ritobegron.Approved, Investigational, Withdrawn
SilodosinSilodosin may decrease the vasoconstricting activities of Ritobegron.Approved
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Ritobegron.Approved
SufentanilRitobegron may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Ritobegron.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Ritobegron.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
TapentadolRitobegron may increase the analgesic activities of Tapentadol.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Ritobegron.Approved
TerfenadineRitobegron may decrease the sedative activities of Terfenadine.Approved, Withdrawn
TesmilifeneRitobegron may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Ritobegron.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of Ritobegron.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Ritobegron.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Ritobegron.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Ritobegron.Approved
ThonzylamineRitobegron may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Ritobegron.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Ritobegron.Approved, Investigational
TilidineRitobegron may increase the analgesic activities of Tilidine.Experimental
TolazolineTolazoline may decrease the vasoconstricting activities of Ritobegron.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypertensive activities of Ritobegron.Approved
TramadolRitobegron may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastRitobegron may decrease the sedative activities of Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypertensive activities of Ritobegron.Approved, Investigational
TrazodoneTrazodone may decrease the vasoconstricting activities of Ritobegron.Approved, Investigational
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Ritobegron.Approved, Investigational
TrifluperidolTrifluperidol may decrease the stimulatory activities of Ritobegron.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Ritobegron.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Ritobegron.Experimental
TrimipramineTrimipramine may increase the stimulatory activities of Ritobegron.Approved
TripelennamineRitobegron may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineRitobegron may decrease the sedative activities of Triprolidine.Approved
TritoqualineRitobegron may decrease the sedative activities of Tritoqualine.Approved
TromethamineTromethamine may decrease the excretion rate of Ritobegron which could result in a higher serum level.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Ritobegron.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Ritobegron.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Ritobegron.Experimental
VerapamilVerapamil may decrease the vasoconstricting activities of Ritobegron.Approved
ZiprasidoneZiprasidone may decrease the stimulatory activities of Ritobegron.Approved
ZotepineZotepine may decrease the stimulatory activities of Ritobegron.Approved, Investigational, Withdrawn
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Ritobegron.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
9820882
PubChem Substance
347828386
ChemSpider
7996631
ChEMBL
CHEMBL2107773

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentOveractive Bladder (OAB)1
3CompletedTreatmentOveractive Bladder1
3WithdrawnTreatmentOveractive Bladder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0103 mg/mLALOGPS
logP1.79ALOGPS
logP0.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.73ChemAxon
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area99.02 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity103.67 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
Phenethylamines / Phenylpropanes / p-Xylenes / Phenoxy compounds / Phenol ethers / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers / Aralkylamines / 1,2-aminoalcohols / Amino acids
show 8 more
Substituents
Phenoxyacetate / Phenethylamine / Phenylpropane / Phenoxy compound / Phenol ether / P-xylene / Xylene / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Phenol
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:19 / Updated on July 02, 2018 19:32